Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT) launched an Early Access Program on Jan 8, 2026 to provide select researchers with initial access to its single-molecule proteomics platform using the company's Iterative Mapping method, beginning with a validated tau proteoforms assay.
The program offers exclusive use for an initial group, support for data interpretation and custom assay development, and aims to accelerate Alzheimer’s and neurodegenerative research. A Nautilus preprint and early external deployment at the Buck Institute reported mapping of up to 768 distinct tau proteoforms across brain regions, and the company will host a webinar on Jan 14, 2026 to present updated collaboration data.
Positive
- Launch of Early Access Program signaling commercial progress
- Iterative Mapping enables single-molecule proteoform analysis
- External deployment mapped up to 768 distinct tau proteoforms
- Program includes support for data interpretation and custom assays
Negative
- Access limited to an exclusive participant group, restricting immediate scale
- Validation described in a Nautilus preprint rather than peer-reviewed journal
- Platform capabilities described as still advancing beyond initial offerings
News Market Reaction – NAUT
On the day this news was published, NAUT declined NaN%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NAUT rose 18.72% with strong volume, while key peers showed modest mixed moves: CSBR +2.58%, IPA +3.5%, QNCX +0.34%, SEER +1.34%, and EXOZ -5.71%. Momentum scanner names ANIX (+6.71%) and ATRA (+15.06%) also moved up but without same-day news. The magnitude of NAUT’s move and the divergence of some peers support a stock-specific reaction to the early access launch.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Platform deployment milestone | Positive | +39.1% | First external field evaluation unit showing reproducible tau proteoform data. |
| Oct 28 | Earnings and pipeline | Positive | +5.9% | Q3 results with lower expenses and guidance toward 1H 2026 early access. |
| Oct 07 | Earnings announcement notice | Neutral | +0.1% | Scheduling of Q3 2025 results call and webcast without new operational data. |
| Aug 27 | Investor conferences | Neutral | -0.5% | Participation in September healthcare and investor conferences with no new data. |
| Jul 31 | Earnings and collaborations | Positive | +0.0% | Q2 results and new tau collaborations; platform progress but flat price reaction. |
Operational and platform milestones, especially around tau proteoforms and external deployments, have previously coincided with strong positive price reactions, while routine conferences and some earnings events drew limited moves.
Over the last six months, Nautilus has consistently highlighted progress toward commercializing its single-molecule proteomics platform. On Jul 31, 2025, Q2 results featured the first Iterative Mapping manuscript and new tau collaborations. Subsequent Q3 updates on Oct 28, 2025 emphasized cost reductions and expectations for early access in 1H 2026. A key milestone came on Nov 3, 2025 with successful installation and 6‑month testing of the first field evaluation unit at the Buck Institute, which saw a strong +39.1% price reaction. Today’s early access launch and tau assay offering build directly on that external validation trajectory.
Market Pulse Summary
This announcement marked a transition from development to early external use, launching an Early Access Program centered on a tau proteoforms assay and Iterative Mapping. The news highlighted validation work at the Buck Institute, including mapping up to 768 tau proteoforms, and pointed to an upcoming January 14, 2026 webinar for additional data. Investors tracking the story may watch adoption by early users, assay performance in Alzheimer’s research, and the path toward broader proteomics offerings.
Key Terms
single-molecule medical
proteomics medical
proteome medical
proteoforms medical
post-translational modifications medical
mass spectrometry medical
Iterative Mapping technical
assay medical
AI-generated analysis. Not financial advice.
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease research
SEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoforms assay as its first offering. The program makes Nautilus' Iterative Mapping approach to measuring proteins and their variants available to an exclusive group of researchers.
Nautilus’ Iterative Mapping method enables single-molecule analysis of proteins and proteoforms and is designed to achieve comprehensive proteome coverage and detail at scale. The method empowers researchers to precisely map combinatorial patterns of post-translational modifications on individual proteins and study how those patterns evolve over the course of diseases such as Alzheimer’s and other neurodegenerative disorders. This high level of resolution makes it possible to uncover biological insights that are difficult or impossible to obtain with conventional proteomics approaches such as traditional affinity-based methods and mass spectrometry.
The Early Access Program represents a key milestone in Nautilus’ path to commercialization, demonstrating the platform’s expected readiness for external use as the company advances capabilities in the future, including additional targeted proteoform analyses, broadscale proteomics, and beyond. Participants will receive support from Nautilus for guidance on data interpretation, quantification, and analysis, supporting rapid adoption and the generation of actionable biological insights.
"Through years of validation, we’ve shown that our platform delivers reproducible, high-quality proteomic data with a level of resolution and scale that differentiates it from other approaches. These capabilities give us the confidence to launch the Early Access Program, knowing our customers will be set up for success from the outset," said Sujal Patel, co-founder and CEO of Nautilus. "We are thrilled to first offer our proprietary tau proteoforms assay, which several of our partners at world-class research institutions are already harnessing for breakthrough Alzheimer’s research, to kick off this new era for proteomics."
The tau proteoforms assay demonstrates the strong performance and accessibility of the Nautilus Platform. A Nautilus preprint debuting the assay details the platform's capabilities in analyzing Alzheimer's disease brain samples, providing initial validation of its accuracy, sensitivity, dynamic range, and reproducibility for interrogating billions of single-protein molecules at scale.
Independently, researchers at the Buck Institute for Research on Aging are using Nautilus' first externally deployed instrument to map up to 768 distinct tau proteoforms across different brain regions. This work has revealed region-specific proteoform patterns associated with disease progression, opening new avenues for studying neurodegenerative biology. Successful adoption by first-time users at the Buck Institute reinforces the platform’s accessibility and commercial readiness for research use.
In addition to standard tau assays for Alzheimer's and neurodegenerative research, the Early Access Program offers exclusive development partnerships to support the creation of custom assays tailored to specific research applications.
Researchers interested in gaining early access to the Nautilus platform, either through the standard tau assay service or through custom assay development, can learn more at nautilus.bio/nautilusEAP/.
Nautilus will also host a webinar, “Advancing next-generation proteomics with single-molecule Iterative Mapping,” on January 14, 2026, at 9:00 AM PT, highlighting the quantitative benefits of Iterative Mapping for proteomics analysis and presenting updated data from the Buck Institute research collaboration. Register here to view the webinar on demand.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, expectations with respect to the timing of the commercial launch and applicability of Nautilus’ product platform in biological research, and the functionality and performance of Nautilus’ product platform, its potential impact on expanding biomedical research, and enabling scientific explorations and discovery, and the present and future capabilities. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will continue to require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Nautilus Media Contact
press@nautilus.bio
Nautilus Investor Contact
investorrelations@nautilus.bio
FAQ
What did Nautilus (NAUT) announce on January 8, 2026 about an Early Access Program?
What is the tau proteoforms assay offered by Nautilus (NAUT)?
How many tau proteoforms did early Nautilus (NAUT) users map with the platform?
Can researchers request custom assays through Nautilus (NAUT) Early Access Program?
When is Nautilus (NAUT) hosting the webinar about its Iterative Mapping platform?
